INNO2VATE CONVERSION – Phase 3, Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Oral Vadadustat for the Maintenece Treatment of Anemia in Subjects with Dialysis-Dependent Chronic Kidney Disease (DD-CKD) (Protocol # AKB-6548-CI-0017)

Study Details
This is a multicenter, randomized, open-label, active-controlled Phase 3 study of the efficacy and safety of vadadustat versus darbepoetin alfa for the maintenance treatment of anemia in subjects with DD-CKD

Learn More NCT number

Principal Investigators

  • Eric Brown, MD
Akebia Therapeutics
Maryanne Ducey, DC, RN at 203-358-8879